Asterias concludes recruitment of initial safety cohort of SCiStar Phase 1/2a trial
Asterias announced the third patient was successfully dosed at Chicago-based Rush University Medical Center in a Phase 1/2a clinical trial evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical SCI. August 31, 2015